Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant endocrine therapy plus CDK4/6 inhibitor for HR+/HER2- inoperable breast cancer after poor response to neoadjuvant chemotherapy
ChiCTR2400088944Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tamoxifen in breast cancer, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: objective response rate. Started Aug 2024; status: recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400088944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088944.